Abstract
Background: Mortality and morbidity are increased in patients experiencing drug-drug interactions. Unfortunately, there is a paucity of literature describing clinically significant drug-drug interactions occurring in the intensive care unit (ICU). Knowing the clinically significant drug-drug interactions allows the opportunity for prevention through knowledge and computer-assisted programmes.
Objective: To identify significant potential drug-drug interactions occurring in the cardiovascular ICU (CCU) and the cardiothoracic ICU (CTICU).
Study Design: Prospective, observational study conducted over a total of 8 weeks in February and March 2009.
Setting: CCU and CTICU in a major academic medical centre (Presbyterian Hospital, University of Pittsburgh Medical Centre).
Patients: All adult patients (≥18 years of age) admitted during 1 month in each ICU.
Intervention: Micromedex® and Lexi-Interact™ interaction databases were used to screen each patient’s medication profile daily for the presence of potentially interacting drug pairs that would be considered a potential drug-drug interaction. A severity assessment using these databases was completed after a potential drug-drug interaction was identified.
Primary Outcome Measure: The frequency of significant drug-drug interactions, including those that were considered major or contraindicated, according to two commercially available interaction databases.
Results: Evaluations of 400 patient medication profiles were conducted, resulting in 225 profiles possessing one or more potential drug-drug interactions. A total of 1150 potential interactions were identified, resulting in 287.5 potential interactions per 100 patient-days. Of the 1150 potential drug-drug interactions, 458 were unique interacting drug pairs; 5–9% of the potential interactions were considered major or contraindicated. Many of the significant and frequent potential interactions involved blood coagulation modifiers, potential interactions that could result in QTc prolongation, and cytochrome P450 inhibition. Micromedex® and Lexi-Interact™ agreed on the severity ratings in 20.5% of the potential interactions.
Conclusions: Significant potential drug-drug interactions occur in the CCU and CTICU, highlighting the need for active surveillance to potentially prevent patient harm. Clinicians should also consider using two references for identifying interactions, due to the lack of congruence between sources.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kohn LT, Corrigan JM, Donaldson MS, editors. To err is human, building a safer health system. Washington, DC: National Academy Press, 2000
Köhler GI, Bode-Böger SM, Busse R, et al. Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther 2000; 38: 504–13
Eslami S, de Keizer NF, Abu-Hanna A. The impact of computerized physician medication order entry in hospitalized patients: a systematic review. Int J Med Inform 2008; 77(6): 365–76
Kuperman GJ, Bobb A, Payne TH, et al. Medication-related clinical decision support in computerized provider order entry systems: a review. J Am Med Inform Assoc 2007; 14(1): 29–40
Halkin H, Katzir I, Kurman I, et al. Preventing drug interactions by online prescription screening in community pharmacies and medical practices. Clin Pharmacol Ther 2001; 69: 260–5
Glassman PA, Simon B, Belperio P, et al. Improving recognition of drug interactions: benefits and barriers to using automated drug alerts. Med Care 2002; 40: 1161–71
Chrischilles EA, Fulda TR, Byrns PJ, et al. The role of pharmacy computer systems in preventing medication errors. J Am Pharm Assoc 2002; 42: 439–48
Roberts JS, Watrous ML, Schulz RM, et al. Quantifying the clinical significance of drug-drug interactions: scaling pharmacists’ perceptions of a common interaction classification scheme. Ann Pharmacother 1996; 30: 926–34
Weingart SN, Simchowitz B, Padolsky H, et al. An empirical model to estimate the potential impact of medication safety alerts in patients safe health care utilization, and cost in ambulatory care. Arch Intern Med 2009; 169(16): 1465–73
Paterno MD, Maviglia SM, Gorman PN, et al. Tiering drug-drug interaction alerts by severity increases compliance rates. J Am Med Inform Assoc 2009; 16: 40–6
van Roon EN, Flikweert S, le Comte M, et al. Clinical relevance of drug-drug interactions: a structured assessment procedure. Drug Saf 2005; 28: 1131–9
Shinn AF, Collins DN, Hoops EJ. Drug interactions of common CCU medications. Am J Nurs 1974; 74(8): 1442–6
Streetman DS. Metabolic basis of drug interactions in the intensive care unit. Crit Care Nurs Q 2000; 22(4): 1–13
Monaghan MS, Falls L, Olsen KM. Potential drug interactions with H2-receptor block antagonists in intensive care unit patients. Hosp Pharm 1993; 28(4): 296–305
Spriet I, Meersseman W, de Hoon J, et al. Mini series, II — clinical aspects: clinically relevant CYP450-mediated drug interactions in the ICU. Intensive Care Med 2009; 35: 603–12
Cullen DJ, Sweitzer BJ, Bates DW, et al. Preventable adverse drug events in hospitalized patients: a comparative study of intensive care and general care units. Crit Care Med 1997; 25(8): 1289–97
Kane-Gill SL, Kowiatek JG, Weber RJ. A comparison of voluntarily reported medication errors in intensive care and general care units. Qual Saf Health Care. In press
Micromedex® healthcare series: interactions (updated periodically). Greenwood Village (CO): Thomson Reuters (Healthcare) Inc. [online]. Available from URL: http://www.thomsonhc.com/hcs/librarian?submit=I+have+read+the+above+notice+-+Start+MICROMEDEX [Accessed 2008 Nov 1]
Lexi-Interact Online. Up-to-date [online]. Available from URL: http://www.uptodate.com/crlsql/interact/frameset.jsp. [Accessed 2008 Nov 1]
Kane-Gill SL, Devlin JW. Adverse drug event reporting in the intensive care units: a survey of current practice. Ann Pharmacother 2006; 40: 1267–73
Edlavitch SA. Adverse drug event reporting: improving the low US reporting rates. Arch Intern Med 1988; 148(7): 1499–503
Lopez LM. Clinical challenges of bleeding in percutaneous coronary intervention. Am J Health Syst Pharm 2003; 60 Suppl. 3: S8–14
Iribarren JL, Jimenez JJ, Hernandez D, et al. Postoperative bleeding in cardiac surgery. Anesthesiology 2008; 108: 596–602
Dacey LJ, Munoz JJ, Baribeau YR, et al. Re-exploration for hemorrhage following coronary artery-bypass grafting: incidence and risk factors. Arch Surg 1998; 133: 442–7
Unsworth-White MJ, Herriot A, Valencia O, et al. Resterotomy for bleeding after cardiac operation: a marker for increased morbidity and mortality. Ann Thorac Surg 1995; 59: 664–7
Orgeas MG, Timsit JF, Soufir L. Impact of adverse events on outcomes in intensive care unit patients. Crit Care Med 2008; 3 6(7): 2041–7
Mangus D, Rodgers S, Avery AJ. GP’s views on computerized drug interaction alerts: questionnaire survey. J Clin Pharm Ther 2002; 27: 377–82
Reason J. Human error. Cambridge: Cambridge University Press, 1990
Institute of Safe Medication Practices. ISMP’s list of high alert medications, 2008 [online]. Available from URL: http://www.ismp.org [Accessed 2009 Apr 9]
Abarca J, Malone DC, Armstrong EP, et al. Concordance of severity ratings provided in four drug interaction compendia. J Am Pharm Assoc (2003) 2004; 44: 136–41
Juntti-Patinen L, Neuvonen PJ. Drug-related deaths in a university central hospital. Eur J Clin Pharmacol 2002; 58: 479–82
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Smithburger, P.L., Kane-Gill, S.L. & Seybert, A.L. Drug-Drug Interactions in Cardiac and Cardiothoracic Intensive Care Units. Drug-Safety 33, 879–888 (2010). https://doi.org/10.2165/11532340-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11532340-000000000-00000